Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (NASDAQ: JUNS) approved a 1-for-75 reverse stock split of its common stock, authorized by shareholders on July 22, 2026. The reverse split becomes legally effective at 4:01 p.m. ET on August 6, 2026, with post-split trading on Nasdaq under the existing symbol JUNS and new CUSIP 48208B 302 starting August 7, 2026.
The move is intended to increase the per-share trading price and help regain compliance with Nasdaq’s minimum bid requirement. Outstanding shares will be reduced from approximately 57,756,143 to about 770,081, while authorized shares remain unchanged. No fractional shares will be issued; holders instead receive cash in lieu of fractional entitlements.
Jupiter Neurosciences (NASDAQ: JUNS) signed a definitive license agreement with PharmAla Biotech Holdings for perpetual, exclusive U.S. rights to ALA-002, a patented, FDA-designated Novel Chemical Entity based on non-racemic MDMA. The transaction is valued at up to $100 million, excluding ongoing royalties, and converts Jupiter from a single-program to a dual clinical-stage CNS company alongside its Phase II Parkinson’s program JOTROL.
According to Jupiter, deal terms include a $3.3 million upfront payment ($1.5 million cash and $1.8 million in JUNS stock with a 120-day lock-up), a $3.3 million Phase 3 first-patient-in milestone, a $20 million U.S. NDA approval milestone, and commercial milestones of $10 million, $30 million, and $33.3 million at cumulative U.S. net sales of $333 million, $1 billion, and $2 billion, respectively. A 3% royalty on net sales begins after the third commercialization milestone. PharmAla will continue to manufacture ALA-002 for Jupiter under negotiated commercial terms, and management highlights alignment with a 2026 U.S. Executive Order aimed at accelerating psychedelic therapies.
Jupiter Neurosciences (Nasdaq:JUNS) appointed health care economist Dr. Tomas J. Philipson to its Board, effective June 26, 2026. He will serve on the Audit and Compensation Committees.
His equity package includes options for 90,000 shares plus 446,428 shares as a performance-aligned retainer vesting over 36 months.
Jupiter Neurosciences (NASDAQ:JUNS) has begun enrolling patients in its Phase 2a RESET trial of oral candidate JOTROL™ for Parkinson’s disease. The 30-patient, 12-week, randomized, double-blind, placebo-controlled study focuses on safety, tolerability and pharmacokinetics, with secondary biomarker endpoints.
According to Jupiter Neurosciences, JOTROL™ showed ~9-fold higher plasma bioavailability versus conventional resveratrol, measurable CSF levels, and no serious adverse events in a 24‑subject Phase 1 study. An FDA IND was cleared in November 2025. Parkinson’s disease affects 1.1 million U.S. patients, with a 2024 global treatment market of $5.65 billion.
Jupiter Neurosciences (NASDAQ:JUNS) closed a registered direct offering of 7,142,858 common shares, raising approximately $2.0 million in gross proceeds. The company indicates the capital extends cash runway for its Parkinson’s program, supports debt reduction, and funds its Phase 2a RESET trial of JOTROL in Parkinson’s disease.
Preclinical data showed statistically significant neuroprotective effects that supported an IND granted in November 2025.
Jupiter Neurosciences (NASDAQ:JUNS) priced a registered direct offering of 7,142,858 common shares, expected to raise approximately $2.0 million in gross proceeds. D. Boral Capital is exclusive placement agent, with closing targeted on or about May 21, 2026, under an effective Form S-3 shelf registration.
Jupiter Neurosciences (NASDAQ:JUNS) signed a $100 million term sheet for exclusive, perpetual U.S. rights to ALA-002, PharmAla Biotech’s next-generation MDMA therapeutic. Upfront consideration totals $3.33 million, split between $1.50 million cash and $1.83 million in JUNS shares, plus milestones and single-digit royalties.
Jupiter will escrow $600,000, usable as a reverse termination fee if no definitive agreement is signed within 90 days. ALA-002 is an FDA-recognized Novel Chemical Entity, designed for improved cardiovascular safety and reduced abuse liability versus racemic MDMA.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 9:00 AM ET at 48 Wall Street (the original Bank of New York). Christer Rosén, chairman and CEO, will deliver the company presentation.
The summit runs May 4–5, 2026, and features company presentations, fireside chats, one-on-one meetings, and networking for public and private company executives, fund managers, and family offices. Invitation requests available via the summit website.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq in New York City. Christer Rosén, chairman and CEO, will discuss recent performance and future growth plans and participate in investor meetings and panel sessions.
The conference hosts presenting companies, fireside chats, facilitated 1:1 investor meetings and sponsors from the capital markets ecosystem.
Jupiter Neurosciences (NASDAQ: JUNS) appointed Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board, adding direct distribution expertise across compounding pharmacies and wellness channels. The company cites an addressable U.S. nutraceutical market of over $1.5 billion. Nugevia™ uses JOTROL™ micellar delivery and includes three formulations: PWR, MND, and GLO. The JOTROL platform supports Jupiter’s clinical pipeline, including a Phase IIa Parkinson’s trial that received FDA clearance. Products are currently direct-to-consumer at the company website, and Jupiter is expanding into practitioner-led channels to leverage clinical-grade bioavailability data.